PNOĒ is preparing to launch PNOĒ 2.0 on October 1, introducing a self-service version of its metabolic testing system designed to reduce the need for a trained operator. The Massachusetts-based company says users will be able to put on the mask, start the test, and breathe normally for about eight minutes while the device measures oxygen consumption and carbon dioxide output. The update is intended to make breath-based metabolic testing easier to deploy across a broader range of wellness and fitness settings.
A More Accessible Testing Format
The company’s existing system requires trained staff to administer the test, a limitation that can restrict where the technology is offered. With the new self-service model, PNOĒ expects its system could become more practical for gyms and potentially pharmacies that do not have dedicated testing personnel. The redesigned device is also smaller, incorporates fewer parts, and is intended to improve reliability compared with the previous version.
Measuring Key Metabolic Indicators
PNOĒ says its platform analyzes 23 biomarkers related to respiratory and metabolic performance and converts the results into recommendations focused on training, nutrition, and wellness. Among the measurements are VO₂ max, resting metabolic rate, and metabolic flexibility, indicators used to assess aerobic capacity, energy expenditure, and how effectively the body shifts between different energy sources. The system combines these measurements with software designed to translate test results into practical wellness guidance.
Designed for Shared Use
The new system is structured so that its electronics can be detached from the silicone mask and straps, allowing the main hardware to be shared while users keep their own mask components. This configuration is intended to support deployment in commercial environments where multiple customers may use the same testing equipment. PNOĒ has simplified the device as part of its broader effort to make metabolic testing easier to integrate into routine wellness services.
Wellness Rather Than Medical Diagnosis
Despite its focus on health-related measurements, PNOĒ is positioning the product as a wellness device rather than a medical diagnostic system. The device is not cleared by the U.S. Food and Drug Administration, and the company says it does not provide medical recommendations based on test results. PNOĒ has indicated that its growing breath-data set could eventually contribute to identifying health problems, although full diagnostic capabilities remain years away and would require regulatory approval.
Business Model and Market Reach
PNOĒ sells its technology to businesses rather than directly to consumers, with customers including Equinox, Four Seasons, Red Bull, the NBA, Mount Sinai Health System, and Restore Hyper Wellness. Businesses pay monthly subscriptions ranging from about $400 to more than $1,000 for hardware, software, training, and marketing support. Around 85% of the company’s current business comes from the United States, making it PNOĒ’s dominant market.
Funding and Expansion Plans
The company has raised about $22 million to date, including a recently closed $11 million financing round, as it continues to scale its operations. PNOĒ employs approximately 110 people and says it has recently become profitable while growing by more than 100% annually. The company also plans to pursue a Series B financing round within the next six to 12 months to support its next stage of growth.
PNOĒ 2.0 represents the company’s latest effort to move metabolic testing beyond specialist environments and into more accessible commercial settings. By combining a self-administered test with software-generated wellness insights, PNOĒ is seeking to make respiratory and metabolic measurements easier for businesses to incorporate into their services. The October launch, recent financing, and planned Series B reflect the company’s push to expand adoption while maintaining a clear distinction between wellness guidance and medical diagnosis.